Leukemia

The optimal use of new agents for the treatment of chronic lymphocytic leukemia (CLL) is still being defined, according to Andrew D. Zelenetz, MD, PhD, Medical Director, Quality Informatics, Memorial Sloan Kettering Cancer Center (MSKCC), New York City.
To our knowledge, cases of successful treatment of chronic myeloid leukemia (CML) with low-dose nilotinib (Tasigna) have not been reported. The following case represents our experience with a patient with CML who achieved good response to nilotinib therapy.

Results 1 - 2 of 2